Introduction (Covering Core User Needs: Pain Points & Solutions):
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Integrated Radionuclide Medicine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Integrated Radionuclide Medicine market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nuclear medicine physicians, oncologists, and radiopharmaceutical developers, the ability to both image and treat cancer with the same targeting molecule represents a paradigm shift in precision oncology. Integrated radionuclide drugs are radiopharmaceutical systems that combine radionuclides with targeting molecules (such as peptides, antibodies, and small molecule ligands) through chemical linkage, resulting in both diagnostic and therapeutic capabilities. These drugs leverage the high affinity and selectivity of targeting molecules for specific lesions (such as tumor cells) to precisely deliver the radionuclide to the affected area, achieving the integration of “targeted imaging and targeted therapy,” a so-called “theranostics” model. With advantages such as high specificity, low toxicity and side effects, and the ability to personalize treatment, these drugs are becoming a key area of convergence between precision medicine and nuclear medicine. With FDA approvals of Lutathera (177Lu-DOTATATE) for neuroendocrine tumors (NETs) and Pluvicto (177Lu-PSMA-617) for prostate cancer, theranostic radiopharmaceuticals have entered mainstream oncology practice.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/releases/6093675/integrated-radionuclide-medicine
1. Market Sizing & Growth Trajectory (With 2026–2032 Forecasts)
According to QYResearch’s proprietary market data, the global market for Integrated Radionuclide Medicine was valued at US$1,436 million in 2025 and is projected to reach US$3,360 million by 2032, growing at a CAGR of 13.1% from 2026 to 2032. This explosive growth is driven by three converging factors: (1) FDA approvals and commercial success of Lutathera and Pluvicto, (2) expanding pipeline of theranostic radiopharmaceuticals, and (3) increasing PET-CT and SPECT-CT installations worldwide.
By drug type, integrated diagnostic and therapeutic radionuclide drugs (theranostics) dominate with approximately 60% of market revenue (higher value per dose). Diagnostic radionuclide drugs account for 40%. By application, healthcare industry (hospitals, clinics, nuclear medicine centers) accounts for approximately 70% of market revenue, nuclear medicine industry for 20%, and biomedical research and development for 10%.
2. Technology Deep-Drive: Theranostic Pairs, Radionuclide Selection, and Targeting
Technical nuances often overlooked:
- Theranostics for precision oncology concept: Same targeting molecule (ligand) labeled with diagnostic radionuclide (imaging) or therapeutic radionuclide (treatment). Diagnostic: 68Ga, 64Cu, 89Zr (PET); 99mTc, 111In (SPECT). Therapeutic: 177Lu, 90Y, 225Ac, 131I, 212Pb. Theranostic pair example: 68Ga-DOTATATE (diagnostic) + 177Lu-DOTATATE (therapeutic) for NETs. 68Ga-PSMA-11 + 177Lu-PSMA-617 for prostate cancer.
- Targeted imaging and therapy mechanisms: Peptide receptor radionuclide therapy (PRRT) – somatostatin receptor (SSTR) targeting for NETs. PSMA-targeted therapy for prostate cancer. Fibroblast activation protein (FAP) targeting for solid tumors (investigational). HER2, PD-L1, other targets in development.
Recent 6-month advances (October 2025 – March 2026):
- Novartis – Lutathera (177Lu-DOTATATE) approved for NETs (2018). Pluvicto (177Lu-PSMA-617) approved for mCRPC (2022). Price: US$45,000-50,000 per dose.
- Bayer AG – Xofigo (223Ra-dichloride) for bone metastases in mCRPC. Price: US$15,000-20,000 per dose.
- Telix Pharmaceuticals – Illuccix (68Ga-PSMA-11) diagnostic PET agent (FDA approved 2021). Price: US$500-1,000 per dose.
3. Industry Segmentation & Key Players
The Integrated Radionuclide Medicine market is segmented as below:
By Drug Type (Therapeutic vs. Diagnostic):
- Diagnostic Radionuclide Drugs – 68Ga-DOTATATE, 68Ga-PSMA-11, 64Cu-DOTATATE, 99mTc-Sestamibi, 18F-FDG. Price: US$200-1,000 per dose.
- Integrated Diagnostic and Therapeutic Radionuclide Drugs – 177Lu-DOTATATE, 177Lu-PSMA-617, 90Y-DOTATATE, 225Ac-PSMA, 131I-MIBG, 223Ra-dichloride. Price: US$15,000-50,000 per dose. Largest segment.
By Application (End-Use Sector):
- Healthcare Industry (hospitals, clinics, nuclear medicine centers) – 70% of 2025 revenue.
- Nuclear Medicine Industry (radiopharmaceutical manufacturers, distributors) – 20% of revenue.
- Biomedical Research and Development Industry (pharma R&D, academic research) – 10% of revenue.
Key Players (2026 Market Positioning):
Global Leaders: Novartis (Switzerland, Lutathera, Pluvicto), Bayer AG (Germany, Xofigo), Lantheus Holdings (USA, PYLARIFY), Telix Pharmaceuticals (Australia, Illuccix), Curium (France/USA), ITM Radiopharma (Germany), POINT Biopharma Global (USA), RadioMedix (USA), Clarity Pharmaceuticals (Australia), ARTBIO (USA), RayzeBio (USA), Convergent Therapeutics (USA), Mariana Oncology (USA), Ratio Therapeutics (USA), Advanced Accelerator Applications (Novartis, France), Cardinal Health (USA), GE HealthCare (USA), Jubilant Pharma (India), IRE ELiT (Belgium), NTP Radioisotopes (South Africa).
Chinese Leaders: China Isotope & Radiation (China), Yantai Dongcheng Biochemicals (China), Beijing Sinotau International Pharmaceutical Technology (China), Hexin Pharmaceutical Technology (China), Fulian Pharmaceuticals (China).
独家观察 (Exclusive Insight): The integrated radionuclide medicine market is concentrated with Novartis (≈40-45% market share, Lutathera + Pluvicto), Bayer (≈10-15%, Xofigo), and Lantheus (≈5-10%, PYLARIFY) as top players. Novartis dominates the therapeutic radiopharmaceutical market (NETs, prostate cancer). Bayer (Xofigo) is #2. Lantheus (PYLARIFY) and Telix (Illuccix) lead in diagnostic PSMA agents. Theranostic approach: diagnostic scan identifies patients who are candidates for therapy (patient selection). Same ligand, different radionuclide (68Ga/64Cu for imaging, 177Lu/225Ac for therapy). Personalized dosimetry: 177Lu therapy dose adjusted based on pre-therapy imaging (patient-specific tumor uptake, organ dosimetry). Supply chain: 177Lu produced in nuclear reactors (Netherlands, Russia, Australia, China, USA). 225Ac produced from 229Th decay (limited supply) or high-energy accelerators (new sources). Short half-life (177Lu 6.6 days, 225Ac 10 days) requires rapid delivery. Reimbursement: Pluvicto US$45,000-50,000 per dose (4-6 doses per patient). Lutathera US$40,000-45,000 per dose (4 doses). Covered by Medicare, commercial insurance. Expanding indications: NETs (Lutathera), prostate cancer (Pluvicto). Pipeline: PSMA-617 in earlier lines of therapy, FAPI-based theranostics for other solid tumors (breast, lung, pancreatic). China market: domestic theranostic radiopharmaceuticals under development (China Isotope & Radiation, Yantai Dongcheng, Sinotau, Hexin, Fulian). Regulatory pathway: FDA/EMA approval required for international markets; NMPA approval for China.
4. User Case Study & Policy Drivers
User Case (Q1 2026): Pluvicto (177Lu-PSMA-617) for mCRPC. Key performance metrics (Phase III VISION trial):
- Median overall survival: 15.3 months (Pluvicto + SOC) vs. 11.3 months (SOC alone)
- Radiographic progression-free survival (rPFS): 8.7 months vs. 3.4 months
- PSA response (≥50% reduction): 46% vs. 7%
- Grade 3-4 adverse events: 33% vs. 19%
- Cost per patient: US$225,000 (4-6 doses)
Policy Updates (Last 6 months):
- FDA – Radiopharmaceutical guidance (December 2025): Clarifies theranostic drug development (diagnostic + therapeutic). Streamlined approval for diagnostic companion to therapeutic.
- CMS – Outpatient reimbursement (January 2026): Covers Pluvicto, Lutathera under Part B. ASP (average sales price) + 6% reimbursement.
- China NMPA – Theranostic radiopharmaceuticals (November 2025): Fast-track approval for domestic products. International products require local clinical trial.
5. Technical Challenges and Future Direction
Despite strong growth, several technical challenges persist:
- Radionuclide supply constraints: 177Lu global production capacity limited (200,000-300,000 doses/year). New reactors (Australia, China, USA) coming online. 225Ac scarcity (<100 grams/year globally) limits alpha therapy development.
- Logistics and infrastructure: Short half-life requires rapid delivery. Nuclear medicine infrastructure (hot labs, radiation safety, waste disposal) not available at all hospitals.
- Patient selection: Theranostic approach requires diagnostic scan (68Ga-PSMA-11) to confirm target expression. 30-40% of patients are not eligible (low PSMA expression, PSMA-negative disease).
独家行业分层视角 (Exclusive Industry Segmentation View):
- Discrete clinical theranostic applications (NETs, prostate cancer) prioritize regulatory approval, reimbursement, and radionuclide supply. Typically use Novartis (Lutathera, Pluvicto), Bayer (Xofigo), Lantheus (PYLARIFY), Telix (Illuccix). Key drivers are survival benefit and physician adoption.
- Flow process pipeline and R&D applications (other solid tumors, FAPI, HER2) prioritize novel targets, alpha emitters (225Ac), and theranostic pairs. Typically use Curium, ITM, POINT, RadioMedix, Clarity, ARTBIO, RayzeBio, Convergent, Mariana, Ratio, Advanced Accelerator Applications, Cardinal Health, GE, Jubilant, IRE, NTP, China Isotope & Radiation, Yantai Dongcheng, Sinotau, Hexin, Fulian. Key drivers are clinical trial data and regulatory approval.
By 2030, integrated radionuclide medicine will evolve toward alpha emitters (225Ac, 212Pb) for higher potency, multi-target theranostics (PSMA + FAPI), and personalized dosimetry (patient-specific dosing). Alpha emitters have shorter range (50-100 μm), higher linear energy transfer (LET), more potent DNA damage (double-strand breaks). As theranostics for precision oncology becomes standard for NETs and prostate cancer, integrated radionuclide medicine will expand into breast, lung, pancreatic, and other solid tumors.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
